Jeffrey S Loutit
Doctors Company (United States)(US)
Publications by Year
Research Areas
Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria, Pneumonia and Respiratory Infections, Antimicrobial Resistance in Staphylococcus, Antibiotic Use and Resistance
Most-Cited Works
- → Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases(2015)397 cited
- → Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects(2015)111 cited
- → Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia(2018)73 cited
- → Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose(2004)68 cited
- → Cerebral Sparganosis: Case Report and Review(1990)59 cited
- → Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia(2006)57 cited
- → Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT)(2017)26 cited
- → Meropenem–Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment(2017)12 cited
- → Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients(2017)9 cited
- → Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection(2017)4 cited